PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics to expand gene therapy portfolio
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a biotech firm specializing in the development of gene therapies for rare genetic disorders affecting the central nervous system (CNS). The acquisition, valued at $200 million, includes a mix of $50 million in cash and approximately $150 million […]